However, the bioavailability of these compounds can be very low, is influenced by many factors, and varies greatly among individuals.
The objective of the team is to evaluate the effects of lipid micronutrients on metabolic alterations, e.g., obesity, inflammation, diabetes and insulin sensitivity (including via GLUT4), that are involved in the etiology of vascular and cardiometabolic diseases, taking into account the factors that regulate and affect their bioavailability and metabolism. We are also studying the post-meal metabolism of lipids, particularly chylomicrons (which are the lipoproteins that carry many lipid micronutrients), as post-meal hyperlipidemia is recognized as a risk factor for low-level inflammation, atheromatous cardiovascular disease and mortality. This is achieved through an integrative biology approach using complementary models, ranging from in vitro digestion models to clinical studies, cell cultures, animal models and the use of state-of-the-art analytical techniques such as metabolomics.

1. To understand the cellular and molecular basis of the mechanisms involved in immuno-thrombosis and vascular repair with a specific focus on the interactions between endothelium, circulating cells, endothelial progenitors, NETS and extracellular vesicles.
2. To identify new cellular and molecular targets and to define innovative biomarkers, imaging strategies and biotherapies to define a personalized approach to vascular targeted medicine to improve the early prevention, diagnosis and treatment of cardiovascular disease.

1. characterize the structure/function of these proteins in different cell types, mainly endothelial cells
2. validate these proteins as therapeutic targets in diseases where endothelial dysfunction plays a role using preclinical cellular and mouse models.
3.  generate and clinically validate innovative diagnostic tests and produce new therapeutic approaches targeting AhR and CD146 for precision vascular medicine.